Odyssey Therapeutics has reported encouraging Phase 2a clinical trial results for OD-001, an investigational oral treatment for moderate-to-severe ulcerative colitis, showing clinical remission in 27% of patients receiving the higher dose after 12 weeks. The biotechnology company also identified improvements in inflammatory biomarkers, intestinal tissue activity and disease-associated gene expression, providing additional evidence supporting the drug’s proposed mechanism. Presented at United European Gastroenterology Week 2026, the findings strengthen the rationale for advancing OD-001 into randomized clinical studies, although the absence of a placebo-controlled comparison prevents definitive conclusions about its effectiveness.
The results come as researchers explore new treatment strategies for ulcerative colitis patients who continue experiencing symptoms despite available therapies. Odyssey Therapeutics is developing OD-001 as a selective RIPK2 scaffolding inhibitor, targeting inflammatory signaling pathways that may contribute to persistent intestinal inflammation and tissue injury.
How did OD-001 perform in the completed Phase 2a ulcerative colitis induction study?
Odyssey Therapeutics evaluated OD-001 in a Phase 2a clinical trial involving 56 efficacy-evaluable patients with moderate-to-severe ulcerative colitis. The study used an open-label, dose-ranging design, with participants receiving either 10 mg or 20 mg of OD-001 twice daily during a 12-week induction period. Its primary endpoint measured changes from baseline in the three-component modified Mayo score, which assesses ulcerative colitis activity through clinical symptoms and endoscopic findings.
Across the evaluable population, OD-001 achieved a mean reduction of 2.4 points in the modified Mayo score after 12 weeks, with a reported p-value below 0.001 for the change from baseline. Although statistically significant, this result measures improvement within the treated population rather than superiority over placebo. The distinction is important because symptom changes and other influences during clinical studies can contribute to apparent improvement even without an active treatment effect.
Among the 41 patients receiving the pooled 20 mg twice-daily regimen, 27% achieved clinical remission, while 61% achieved clinical response and 49% achieved symptomatic remission at Week 12. The corresponding rates among 15 patients receiving 10 mg twice daily were 20%, 40% and 27%, respectively. These findings suggest greater numerical treatment activity with the higher dose, although the study was not designed to establish a definitive comparative efficacy advantage between dosing groups.
The company also observed an early symptomatic response among patients receiving 20 mg twice daily. Symptomatic remission reached 21% by Week 2 and increased throughout the induction period without an apparent plateau at Week 12. This pattern suggests that clinical improvement may develop relatively early and continue with treatment, but longer follow-up will be required to determine whether the benefits persist.
The completed induction analysis builds on earlier clinical findings by incorporating the full efficacy-evaluable population and additional biological assessments. The data remain subject to change until database lock, meaning that final validated results may differ from the currently reported findings.
Did OD-001 improve ulcerative colitis outcomes in patients previously treated with advanced therapies?
An important consideration in ulcerative colitis drug development is whether an investigational treatment can benefit patients who have already received biologic medications or other advanced therapies. Although existing treatments have improved disease management, some patients experience inadequate responses, lose treatment benefit over time or discontinue therapy because of adverse effects.
Odyssey Therapeutics examined clinical remission outcomes according to previous treatment exposure. Among patients receiving OD-001 at 20 mg twice daily, clinical remission was reported in 29% of advanced therapy-naïve participants and 23% of those previously exposed to advanced treatments. The respective subgroups included 28 and 13 patients, indicating that the observed numerical differences must be interpreted cautiously.
The findings suggest that OD-001 may demonstrate clinical activity in patients with different treatment histories. However, the small subgroup sizes and lack of a concurrent control group prevent conclusions about its comparative effectiveness or ability to overcome resistance to existing medications.
The company also evaluated patients with severe endoscopic disease, defined by a Mayo Endoscopic Score of 3. Among 19 participants with this degree of intestinal inflammation who received the higher OD-001 dose, 16% achieved clinical remission at Week 12.
These findings are potentially relevant because patients with severe endoscopic inflammation can face a greater burden of persistent symptoms and complications. Demonstrating treatment activity in this population could support further investigation of OD-001 in patients with difficult-to-manage disease.
Nevertheless, the results remain preliminary. Larger randomized studies will be necessary to establish whether OD-001 produces clinically meaningful benefits across different disease severities and previous treatment histories.
Why could OD-001’s RIPK2 inhibition mechanism offer a different approach to intestinal inflammation?
OD-001 is an oral, selective inhibitor of receptor-interacting protein kinase 2, commonly known as RIPK2. This protein participates in innate immune signaling pathways that help the body recognize microbial components and coordinate inflammatory responses.
In ulcerative colitis, dysregulated immune activity contributes to chronic inflammation of the colon and rectum. Multiple signaling pathways can sustain this process, creating opportunities for treatments targeting different components of the immune response.
Odyssey Therapeutics is developing OD-001 to inhibit RIPK2 scaffolding activity, potentially reducing inflammatory signaling upstream of several pathways implicated in intestinal disease. This approach differs from therapies that primarily target individual inflammatory cytokines or immune-cell trafficking.
The company’s new analyses provide biological evidence consistent with the proposed mechanism. Investigators evaluated paired colonic biopsy samples collected at baseline and Week 12, examining changes in gene-expression patterns associated with inflammatory activity.
Treatment was associated with reductions in RIPK2-responsive and downstream inflammatory signatures, including pathways involving interleukin-23, tumor necrosis factor, NF-κB, TL1A and AP-1. Changes were also observed in gene signatures associated with T-cell activity, suggesting broader modulation of inflammatory processes within intestinal tissue.
The findings are notable because clinical symptom improvement alone does not establish that a drug engages its intended biological target. Observing changes in relevant inflammatory pathways alongside clinical outcomes provides additional support for the treatment’s proposed pharmacological activity.
However, these transcriptomic assessments were exploratory. Gene-expression changes cannot independently establish clinical effectiveness or prove that specific pathway modulation caused the observed improvements.
What did inflammatory biomarkers and intestinal biopsy findings reveal about OD-001’s activity?
The Phase 2a analysis also examined established indicators of intestinal and systemic inflammation, providing further information about OD-001’s potential biological effects. Among patients receiving 20 mg twice daily, fecal calprotectin showed a downward trend. This biomarker is commonly used to assess intestinal inflammation in inflammatory bowel disease, although the reported change was not characterized as statistically significant.
Other findings included statistically significant decreases in high-sensitivity C-reactive protein and circulating neutrophil counts, alongside a significant increase in serum albumin. These changes are consistent with reduced systemic inflammatory activity, although they do not independently demonstrate that intestinal disease has entered remission.
Neutrophils are particularly relevant to the treatment’s proposed mechanism because they express RIPK2 and contribute to inflammatory processes associated with ulcerative colitis. The reduction observed during treatment therefore provides additional evidence consistent with the drug’s intended biological activity.
Odyssey Therapeutics also reported reductions in fibrosis-associated gene-expression signatures and increased expression of genes linked to epithelial homeostasis and mucosal healing. These findings suggest that OD-001 may influence biological processes beyond immediate inflammatory signaling.
Chief executive officer Gary D. Glick indicated that the alignment between clinical findings, inflammatory biomarkers and intestinal transcriptomic changes strengthened the company’s confidence in OD-001’s proposed mechanism. Management believes the results support continued development of the 20 mg twice-daily regimen.
Nevertheless, changes in fibrosis-related signatures should not be interpreted as proof that OD-001 reverses established intestinal fibrosis. Similarly, gene-expression patterns associated with mucosal repair do not establish durable mucosal healing without confirmatory clinical and histological assessments.
How safe was OD-001 during the Phase 2a ulcerative colitis study?
Odyssey Therapeutics reported that OD-001 was generally well tolerated throughout the 12-week induction period, with no serious adverse events, serious infections, treatment-related discontinuations or treatment-emergent liver function abnormalities.
Three adverse events in the 20 mg twice-daily group were considered treatment-related, consisting of two cases of fever and one headache. A separate Grade 3 anemia event occurred in the lower-dose group in a patient with pre-existing anemia, but investigators considered it unrelated to OD-001. The event resolved following iron supplementation without treatment discontinuation.
These observations provide encouraging preliminary evidence concerning short-term tolerability, particularly because therapies that modify immune signaling require careful assessment for infection-related and other systemic complications.
However, the study’s small sample size and limited duration prevent reliable detection of uncommon or delayed adverse reactions. The open-label design also introduces potential limitations when evaluating subjective adverse-event reporting. Future randomized trials will therefore need to characterize the treatment’s safety profile in larger populations and assess whether continued administration produces additional risks.
What comes next for OD-001 as Odyssey Therapeutics prepares randomized ulcerative colitis trials?
Odyssey Therapeutics plans to advance OD-001 into two additional clinical studies designed to provide more rigorous evidence of its therapeutic effects. The first will be a randomized, double-blind, placebo-controlled Phase 2b trial evaluating OD-001 as monotherapy in patients with ulcerative colitis. This study will help determine whether the clinical improvements observed in Phase 2a exceed those achieved with placebo.
The second will be a randomized, double-blind Phase 2a combination study evaluating OD-001 alongside vedolizumab, an established treatment that limits immune-cell trafficking into the intestinal tissue. Participants will receive OD-001 plus vedolizumab or vedolizumab plus placebo, allowing investigators to assess the potential additional benefit of RIPK2 inhibition.
The combination strategy is based on targeting complementary aspects of inflammation. While vedolizumab acts on immune-cell trafficking, OD-001 is intended to modulate upstream innate immune signaling, potentially providing a broader therapeutic effect.
The company expects top-line induction results from both studies during the second half of 2027. It has also identified 20 mg twice daily as the projected lowest maximally efficacious dose, based on the completed Phase 2a findings and earlier pharmacology data.
These next studies represent an important transition from exploratory clinical evidence to controlled evaluation. Demonstrating statistically significant benefits against placebo or an active-treatment background will be essential for establishing OD-001’s potential place in ulcerative colitis management.
For patients with moderate-to-severe ulcerative colitis, the prospect of an oral treatment targeting a distinct inflammatory mechanism is encouraging. However, the latest results establish preliminary clinical and biological activity rather than definitive effectiveness, and the forthcoming randomized trials will determine whether OD-001 can deliver reproducible benefits with acceptable long-term safety.
